8 December 2021 - offer for company
The AIM-listed pharmaceutical services company has announced that it has received a cash bid of 883p per share from Triton Investments. This has been recommended by the board of Clinigen although the share price has risen to above the offer price as some investors obviously feel there is the possibility of a higher bid. This could obviously be the case and so investors should hold for now. HOLD
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.